First-quarter 2024 total net sales were $610.8 million, a decrease of 9.8 percent compared to $676.8 million reported for the first quarter of 2023. On a currency-neutral basis, quarterly sales decreased 9.6 percent compared to the same perio... Read more
In an interview with BioPharma BoardRoom, Cem Zorlular, CEO of Er-Kim, shares his personal journey and the driving force behind Er-Kim's mission to tackle the inequity of drug access outside core markets. As a third-generation leader of Er-Ki... Read more
Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2024 ended ... Read more
Broad-based performance drives sales, profits and earnings growth: Total Q1 2024 sales £7.4 billion +10% and +13% ex COVID Vaccines sales +16%, +22% ex COVID. Shingrix £0.9 billion +18%, Arexvy £0.2 billion Specialty Medici... Read more
German Chancellor Olaf Scholz emphasizes significance for Germany as research location at cornerstone laying ceremony Research center to accelerate biopharmaceutical product development Part of Merck’s € 1.5 billion investment pro... Read more
Under Narasimhan's leadership, the company sees significant sales and profit growth across major products, prompting an upward revision of the full-year 2024 guidance. Q1 net sales grew +11% (cc1, +10% USD) with core operating inco... Read more
Ribobay Pharma, a prominent Chinese biopharmaceutical contract research, development, and manufacturing organization (CRDMO), in conjunction with Cytiva, unveils a groundbreaking endeavor set to transform the landscape of oligonucleo... Read more
Biopharmaceutical contract manufacturer SK pharmteco commits to production, testing, and release of Ferring’s U.S. approved ADSTILADRIN® (nadofaragene firadenovec-vncg) The deal assures diversity of supply to meet future long-t... Read more
© 2024 Biopharma Boardroom. All Rights Reserved.
